Quoin Pharmaceuticals, Ltd. — Director's Dealing 2023

Jan 3, 2023

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Quoin Pharmaceuticals, Ltd. (QNRX)
CIK: 0001671502
Period of Report: 2023-01-01

Reporting Person: Dunn Gordon (Chief Financial Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Share Option (right to buy)	$0.0035	2032-04-12	Ordinary Shares (357142800)		Direct

Footnotes

F1: The option vests in four equal annual installments beginning on April 12, 2023.

F2: The number of securities underlying the option and the exercise price are listed in terms of ordinary shares, with five thousand (5,000) ordinary shares of the Issuer represented by one (1) American Depositary Share ("ADS"), which evidences the grant of an option to buy 71,428.56 ADSs at the exercise price of $17.50 per ADS.